AnaptysBio, Inc.
NASDAQ:ANABBiotechnology
Healthcare
$47.40 -1.88%
-$1.07 today
- Market cap
- $1.41B
- Beta
- 0.41
- P/E (TTM)
- -59.7
- EPS (TTM)
- -$0.93
52W Low $11.40High $72.36
Volume 0.51M
Average 0.76M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$19.70M
FY 2025 · Annual
Investing Cash Flow
$228.03M
FY 2025 · Annual
+139.0% YoYFinancing Cash Flow
-$132.61M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (57.8M) | (128.72M) | (163.62M) | (145.23M) | 49.61M |
| Depreciation & Amortization | 2.09M | 2.34M | 2.38M | 2.4M | 2.42M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 15.35M | 27.36M | 33.21M | 34.05M | 36.07M |
| Change in Working Capital | (7.49M) | 6.84M | (324K) | (66.33M) | (80.73M) |
| Accounts Receivables | (876K) | (543K) | (5.43M) | (33.91M) | 6.92M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.74M) | 9.7M | 10.94M | (33.84M) | (87.33M) |
| Other Working Capital | (1.87M) | (2.32M) | (5.83M) | 1.43M | (313K) |
| Other Non-Cash Items | 1.93M | 18.6M | 7.56M | 39.77M | 12.31M |
| Operating Cash Flow | (45.92M) | (73.59M) | (120.8M) | (135.34M) | 19.7M |
| Capital Expenditures | (1.37M) | (358K) | (807K) | (358K) | (87K) |
| Acquisitions (Net) | 0 | 394.49M | 0 | 0 | 0 |
| Purchases of Investments | (118.66M) | (802.5M) | (303.92M) | (380.38M) | (196.41M) |
| Sales of Investments | 158.85M | 408.02M | 449.48M | 476.13M | 424.53M |
| Other Investing Activities | 15K | (394.49M) | 0 | 0 | 0 |
| Investing Cash Flow | 38.84M | (394.85M) | 144.75M | 95.4M | 228.03M |
| Debt Repayment | 0 | 0 | (11.73M) | 34.77M | (76.8M) |
| Common Stock Issued | 2.55M | 11.83M | 2.47M | 100.84M | 14.26M |
| Common Stock Repurchased | 0 | 0 | (50M) | (456K) | (68.63M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 249.75M | 32.19M | (43K) | (8.1M) | (1.45M) |
| Financing Cash Flow | 252.3M | 44.02M | (59.3M) | 127.05M | (132.61M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 245.21M | (424.42M) | (35.34M) | 87.12M | 115.12M |
| Free Cash Flow | (47.29M) | (73.95M) | (121.61M) | (135.7M) | 19.61M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$49.6M
+ D&A$2.4M
+ Stock-Based Comp$36.1M
+ Deferred Tax$0
- Working Capital-$80.7M
+ Other Non-Cash$12.3M
= Operating Cash Flow$19.7M
- Capex-$87.0K
= Free Cash Flow$19.6M
Analysis
FY2025 free cash flow is $19.6M. FCF conversion is 39.5% of net income. Operating cash flow was $19.7M, with capex of -$87.0K. The largest bridge item is Working Capital at -$80.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 | |
| 10-KT | 10-KT filing | Sep 21, 2026 | |
| 8-K | Current report | Sep 21, 2026 |
Does ANAB generate free cash flow?
AnaptysBio, Inc. (ANAB) generated $19.61M of free cash flow in fiscal 2025.
How much operating cash flow does ANAB produce?
Operating cash flow was $19.70M, before capital expenditures of $87,000.00.
Continue the stock analysis
Jump to another research area for this company.